Posted by Michael Wonder on 03 Feb 2018
European Medicines Agency accepts fremanezumab marketing authorisation application
2 February 2018 - Teva seeking EU regulatory approval for anti-CGRP therapy for the prevention of migraine.
Teva Pharmaceutical Industries today announced that the EMA has accepted the marketing authorisation application for fremanezumab, an anti-calcitonin gene-related peptide (CGRP) antibody for the prevention of episodic and chronic migraine in adults.
Fremanezumab is a quarterly or monthly injection that may be administered by a healthcare professional, or self-administered by the patient.
